Soluble Kit receptor blocks stem cell factor bioactivity in vitro.

Abstract:

:Stem cell factor (SCF) is a growth factor that promotes the survival, proliferation, and differentiation of hematopoietic cells. SCF and its receptor, Kit, are normally present in both cell surface and soluble forms. Both forms of Kit can bind SCF. However, the function of soluble Kit is unknown. In order to determine if soluble Kit can modulate SCF activity, we produced a fusion protein, Kit-Fc, comprised of the extracellular domain of murine Kit and the Fc portion of human IgG(1) and investigated its ability to bind 125I-SCF and to inhibit SCF-stimulated hematopoietic colony growth in vitro. Stable cell lines expressing Kit-Fc were generated and Kit-Fc was purified to greater than 95% purity. Scatchard analysis demonstrated that Kit-Fc binds iodinated SCF with high affinity (Kd 570 pM). Kit-Fc also bound to transmembrane SCF displayed on the surface of fibroblasts. The murine mast cell line IC2 was engineered to express murine Kit on the cell surface and was demonstrated to proliferate in the presence of SCF. Kit-Fc completely blocked SCF-stimulated proliferation of IC2-Kit cells, but not IL-3-stimulated growth of IC2-Kit cells, demonstrating the specificity of Kit-Fc. We investigated the ability of Kit-Fc to block SCF-stimulated murine hematopoietic colony growth. Kit-Fc blocked SCF-stimulated erythroid colony growth as effectively as a neutralizing anti-Kit monoclonal antibody, ACK2, but did not block erythropoietin-stimulated erythroid colony growth. Likewise, Kit-Fc blocked SCF-stimulated myeloid colony growth as effectively as ACK2 antibody, but did not block IL-3- or GM-CSF-stimulated myeloid colony growth. These results indicate that a form of soluble Kit binds SCF with high affinity, and can specifically block the ability of SCF to stimulate hematopoietic colony growth, suggesting that one function of soluble Kit may be to modulate SCF bioactivity.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Dahlen DD,Lin NL,Liu YC,Broudy VC

doi

10.1016/s0145-2126(00)00122-3

keywords:

subject

Has Abstract

pub_date

2001-05-01 00:00:00

pages

413-21

issue

5

eissn

0145-2126

issn

1873-5835

pii

S0145212600001223

journal_volume

25

pub_type

杂志文章
  • Benzyl isothiocyanate inhibits murine WEHI-3 leukemia cells in vitro and promotes phagocytosis in BALB/c mice in vivo.

    abstract::Many evidences have shown that dietary intake of cruciferous vegetables could protect against the risk of various types of malignancies. Benzyl isothiocyanate (BITC), one of the compounds from cruciferous vegetables, had shown induced cell cycle arrest and apoptosis in cancer cells. However, there is no available info...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.01.030

    authors: Tsou MF,Peng CT,Shih MC,Yang JS,Lu CC,Chiang JH,Wu CL,Lin JP,Lo C,Fan MJ,Chung JG

    更新日期:2009-11-01 00:00:00

  • A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.

    abstract::Despite initial remissions, most patients with Ph chromosome positive (Ph(+)) acute leukemia (AL) become refractory to tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib. This study was designed to determine if targeting the interleukin-3 receptor (IL-3R) with a diphtheria toxin fusion protein (DT(388)IL...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.12.008

    authors: Kim HP,Frankel AE,Hogge DE

    更新日期:2010-08-01 00:00:00

  • Transfer of the cytidine deaminase cDNA into hematopoietic cells.

    abstract::In order to investigate whether transfer of the cytidine deaminase (CDD) cDNA would increase chemotherapy resistance to cytosine arabinoside (ara-C) we used a retroviral vector expressing both, neomycin phosphotransferase and the CDD cDNA, to transduce hematopoietic cells from cell lines and from murine bone marrow (B...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(99)00128-9

    authors: Flasshove M,Frings W,Schröder JK,Moritz T,Schütte J,Seeber S

    更新日期:1999-11-01 00:00:00

  • Myelodysplastic syndromes in patients under 50 years old: a single institution experience.

    abstract::We report on our experience relating to 62 patients with myelodysplastic syndrome (MDS) aged less than 50 years, seen at our Institution and conservatively treated from July 1983 to December 2000. Patients demographics and clinical features at diagnosis were analysed for their prognostic value on survival and on risk ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.01.003

    authors: Breccia M,Mengarelli A,Mancini M,Biondo F,Gentilini F,Latagliata R,Mandelli F,Alimena G

    更新日期:2005-07-01 00:00:00

  • Characterization of a 4 lncRNAs-based prognostic risk scoring system in adults with acute myeloid leukemia.

    abstract:PURPOSE:The study aims to develop a prognostic scoring system based on prognostic lncRNAs for acute myeloid leukemia (AML). METHODS:Based on lncRNA expression profiles downloaded from The Cancer Genome Atlas (TCGA), differentially expressed long noncoding RNAs (DELs) between good prognosis and bad prognosis samples we...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2019.106261

    authors: Zeng H,Wu H,Yan M,Tang L,Guo X,Zhao X

    更新日期:2020-01-01 00:00:00

  • From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes.

    abstract::A primary mitochondrial defect may be pivotal in the pathogenesis of acquired idiopathic sideroblastic anemia (AISA). The mitochondrial respiratory chain is involved in mitochondrial iron uptake and supply of ferrous iron (Fe2+) for heme synthesis. Mitochondrial DNA (mtDNA) comes into play because several subunits of ...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/s0145-2126(99)00160-5

    authors: Gattermann N

    更新日期:2000-02-01 00:00:00

  • Enhancement of J6-1 human leukemic cell proliferation by membrane-bound M-CSF through a cell-cell contact mechanism II. Role of an M-CSF receptor-like membrane protein.

    abstract::We have isolated an M-CSF-like membrane-associated growth factor from human leukemic J6-1 cells that can enhance the growth and colony formation of J6-1 cells in vitro. Indirect evidence suggests that this membrane-associated M-CSF-like growth factor may do so by stimulating a corresponding receptor co-expressed on th...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(97)00135-5

    authors: Wu KF,Rao Q,Zheng GG,He ZH,Ying HG,Song YH,Chen BD

    更新日期:1998-01-01 00:00:00

  • An autologous tumor vaccine for CLL.

    abstract::Chronic Lymphocytic Leukemia B cells (CLL) are malignant cells which retain at least some functions of normal B cells. Paramount amongst the latter is that when such cells are appropriately stimulated, they are able to present antigens, including any potential tumor antigens, making them excellent choices as a candida...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2018.03.002

    authors: Zhu F,Khatri I,Spaner D,Gorczynski RM

    更新日期:2018-05-01 00:00:00

  • Expressions of the VLA-4, LFA-1 and Mac-1 integrins in eosinophil migration in a case of chronic eosinophilic leukaemia.

    abstract::Migration of eosinophil (Eo) into tissues is a hallmark of chronic eosinophilic leukaemia (CEL), but the exact mechanism involved in cell migration is unknown. We report on a patient with CEL who presented high expressions of VLA-4, LFA-1 and Mac-1 integrins on the Eo surface, increased chemotaxis of Eo to eotaxin, de...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.07.025

    authors: Lima CS,Franco-Penteado CF,Canalli AA,Conran N,Lorand-Metze I,Costa FF,Ferreira HH

    更新日期:2007-05-01 00:00:00

  • Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.

    abstract::FLT3 is a receptor tyrosine kinase involved in the survival of hematopoietic stem cells, and mutations of FLT3 have been reported to be of prognostic significance. This is the first study of FLT3 mutations in pediatric non-promyelocytic AML patients that received the same treatment scheme in single institute. FLT3 int...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.11.006

    authors: Kang HJ,Hong SH,Kim IH,Park BK,Han KS,Cho HI,Shin HY,Ahn HS

    更新日期:2005-06-01 00:00:00

  • Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

    abstract::Peripheral neuropathy (PN), with neuropathic pain as main symptom, represents the dose-limiting toxicity of the proteasome inhibitor bortezomib. Aim of this study was to compare the incidence, risk factors, severity and outcome of PN and neuropathic pain in patient treated with bortezomib up-front or at relapse. We st...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.07.022

    authors: Corso A,Mangiacavalli S,Varettoni M,Pascutto C,Zappasodi P,Lazzarino M

    更新日期:2010-04-01 00:00:00

  • Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific.

    abstract::Internal tandem duplications (ITDs) of the FLT3 gene occur in approximately 20-30% of acute myeloid leukemia (AML) patients. We investigated if FLT3 ITDs could be used as minimal residual disease (MRD) markers for AML patients. Patient-specific polymerase chain reaction (PCR) assays for FLT3 ITDs were developed for fo...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(01)00087-x

    authors: Stirewalt DL,Willman CL,Radich JP

    更新日期:2001-12-01 00:00:00

  • Low-dose radiotherapy (2×2 g) versus low doses and rituximab in the treatment of marginal zone b-cell lymphoma previously untreated.

    abstract::Radiotherapy (RT)is considered the treatment of choice in patients with Extra-nodal marginal zone lymphoma (EMZL) at early stage, but the presence of late toxicities has been limited the acceptance. Recently, low doses of RT LDR) (2 x 2 Gy) and the use of limited fields has been observed that retain the efficacy but e...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2020.106443

    authors: Aviles A,Cleto S

    更新日期:2020-11-01 00:00:00

  • Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Lymphoma Study Group (1984-1987).

    abstract::A total of 854 patients with anti-HTLV-I antibody positive ATL, newly diagnosed from 1983 to 1987, were analyzed for prognostic factors. There were 466 males and 388 females with a mean age of 57.1. Of these 269 (31.5%) were alive with a median follow-up time of 14 months from diagnosis, while 585 (65.5%) were dead wi...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(91)90087-a

    authors:

    更新日期:1991-01-01 00:00:00

  • Molecular characterization and prognostic significance of FLT3 in CML progression.

    abstract::To characterize the molecular mechanisms involved in the transition from the chronic phase to blast crisis in chronic myelogenous leukemia (CML), gene expression profiles of leukemic cells from patients in the chronic and blast crisis phases were analyzed using an 8.7K cDNA chip and real-time PCR. A transient transfec...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.11.008

    authors: Kim KI,Park J,Ahn KS,Won NH,Kim BK,Shin WG,Yoon SS,Oh JM

    更新日期:2010-08-01 00:00:00

  • Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations.

    abstract::Activating mutations of Fms-like tyrosine kinase 3 (Flt3) are the most common genetic abnormalities found in acute myeloid leukemia (AML) and represent potential therapeutic targets. The novel Flt3 inhibitor KRN383 inhibited the autophosphorylation of Flt3 bearing internal tandem duplications (ITDs) and the Asp835Tyr ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.02.028

    authors: Nishiyama U,Yoshino T,Ozai M,Yoshioka R,Fujisawa M,Ogasawara Y,Kitahori M,Yoshioka E,Kubo K,Komeno Y,Kurokawa M,Ogawa S,Chiba S,Osawa T,Kuwaki T,Hirai H,Miwa A

    更新日期:2006-12-01 00:00:00

  • KN-62 analogues as potent differentiating agents of HL-60 cells.

    abstract::KN-62, an inhibitor of the calmodulin-dependent protein kinases (CaMKs), enhances the terminal differentiation of retinoic acid sensitive human myeloid leukemia cell lines. In an effort to identify additional CaMK inhibitors that exhibit more potent activity in triggering leukemia cell differentiation, we synthesized ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.07.022

    authors: Schuler AD,Si J,Mueller L,Simon JA,Collins SJ

    更新日期:2007-05-01 00:00:00

  • Complete variable region deletion in a mu heavy chain disease protein (ROUL). Correlation with light chain secretion.

    abstract::In a patient affected with chronic lymphocytic leukemia with lymphocyte surface mu and kappa determinants and vacuolated bone marrow plasma cells, the serum contained polymers of a truncated mu chain and normal-sized kappa chains. These light chains were present as monomers and covalent dimers in studies performed und...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(93)90129-9

    authors: Cogné M,Aucouturier P,Brizard A,Dreyfus B,Duarte F,Preud'homme JL

    更新日期:1993-06-01 00:00:00

  • Bone marrow B lymphocytes in multiple myeloma and MGUS: Focus on distribution of naïve cells and memory subsets.

    abstract:BACKGROUND/AIMS:Multiple myeloma (MM) is caused by proliferation of clonal plasma cells (cPCs) in bone marrow (BM), associated with numerical and functional defects in immune subsets. An impairment of B cell compartment is involved in onset/progression of the disease. METHODS:By flow cytometry, we studied distribution...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2016.08.008

    authors: Pojero F,Casuccio A,Giambanco C,Bulati M,Buffa S,Di Bassiano F,Gervasi F,Caruso C,Colonna Romano G

    更新日期:2016-10-01 00:00:00

  • Role of stromal and hematopoietic stem cells in Friend spleen focus forming virus effects in continuous bone marrow culture.

    abstract::Replication of the Friend spleen focus forming virus (SFFV) in C3H/HeJ or C57BL/6J mouse continuous bone marrow cultures is associated with an increased cumulative production of pluripotential/hematopoietic stem cells (CFUs), granulocyte-macrophage progenitor cells (GM-CFUc), and total granulocytes, compared to uninfe...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(83)90133-9

    authors: Greenberger JS,Eckner RJ,Sakakeeny MA,Cohen GI

    更新日期:1983-01-01 00:00:00

  • Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy.

    abstract::Imatinib is a tyrosine kinase inhibitor and is now used regularly in chronic myeloid leukaemia therapy in chronic phase with great success. This drug due its very nature of action is suspected to be teratogenic hence the patients are counseled not to get pregnant while on this drug. However in world literature few nor...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.03.007

    authors: Meera V,Jijina F,Shrikande M,Madkaikar M,Ghosh K

    更新日期:2008-10-01 00:00:00

  • 5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.

    abstract::Imatinib is a highly effective drug for the treatment of chronic myeloid leukemia (CML) that targets the BCR-ABL kinase. However, a number of patients have CML that is resistant to Imatinib treatment. In this report, we developed AGM130 as a potential therapeutic drug for Imatinib-resistant CML treatment. The AGM130 c...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.12.017

    authors: Kim WS,Lee MJ,Kim DH,Lee JE,Kim JI,Kim YC,Song MR,Park SG

    更新日期:2013-04-01 00:00:00

  • Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900).

    abstract::We evaluated the efficacy of FISH to detect chromosome anomalies in the evaluation of young (<60 years) patients with AML. Patients were enrolled in E1900, an ECOG clinical trial for AML. The protocol was designed to collect bone marrow or blood for both cytogenetic and FISH studies at study entry (diagnosis). FISH fo...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.07.026

    authors: Vance GH,Kim H,Hicks GA,Cherry AM,Higgins R,Hulshizer RL,Tallman MS,Fernandez HF,Dewald GW

    更新日期:2007-05-01 00:00:00

  • Mouse monoclonal antibodies direct phagocytosis of tumor cells by human monocytes.

    abstract::Human peripheral blood monocytes were found to be capable of phagocytizing human B-non Hodgkin's lymphoma (NHL) cells coated with mouse monoclonal antibodies (MoAbs). The MoAbs used recognized idiotypic determinants on the surface immunoglobulin (Ig) of the tumor cells. MoAbs of IgG1 and IgG2a subclass were equally ef...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(86)90344-9

    authors: Calafat J,Janssen H,Hekman A

    更新日期:1986-01-01 00:00:00

  • Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.

    abstract::Secondary acute lymphoblastic leukemia (s-ALL) is rare and poorly defined and data regarding outcomes post-transplant are lacking. Here, we report a detailed analysis of s-ALL at our Institution. Among 211 eligible patients with ALL from 2006 to 2017, 30 (14%) were defined as s-ALL and the remaining as primary ALL (p-...

    journal_title:Leukemia research

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.leukres.2018.07.024

    authors: Ferraro F,Gao F,Stockerl-Goldstein K,Westervelt P,DiPersio JF,Ghobadi A

    更新日期:2018-09-01 00:00:00

  • Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.

    abstract::Increasing evidence suggest that epigenetic mechanisms (e.g. histone modification by histone deacetylases) play a major role in the pathogenesis of Hodgkin's lymphoma (HL). We treated HL cell lines with the histone deacetylase inhibitor vorinostat and investigated the gene expression profile of these cells by using DN...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.02.021

    authors: Kewitz S,Bernig T,Staege MS

    更新日期:2012-06-01 00:00:00

  • 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.

    abstract::3q26.2/EVI1 rearrangements resulting in EVI1 overexpression play an important role in leukemogenesis and are associated with treatment resistance and a poorer prognosis in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia and BCR-ABL negative myeloproliferative neoplasms. In this...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2017.12.004

    authors: Hu Z,Hu S,Ji C,Tang Z,Thakral B,Loghavi S,Medeiros LJ,Wang W

    更新日期:2018-02-01 00:00:00

  • Monoclonal antibodies raised against K562 cells reacted with human haematopoietic pluripotent stem cells.

    abstract::We describe the properties of three monoclonal antibodies (McAbs) (21H73, 37G7 and 49C12) against K562 cell surface antigens correlated with differentiation induced by 12-O-tetradecanoyl phorbol-13-acetate (TPA). Each of the McAbs immunoprecipitated K562 cell surface antigen with molecular weight (MW) of approximately...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(91)90121-9

    authors: Kubota Y,Tanaka T,Irino S

    更新日期:1991-01-01 00:00:00

  • Monoclonal antibodies in myeloid diseases: prognostic use in acute myeloid leukaemia.

    abstract::Bone marrow cells from 109 patients (median age 60) with newly diagnosed acute myeloid leukaemia (AML) were prospectively immunophenotyped (IP) and the prognostic value of monoclonal antibody (MAB) reactivities was analysed to detect differences in complete remission rates and survival, not only between groups of MAB ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(91)90071-z

    authors: Kristensen JS,Hokland P

    更新日期:1991-01-01 00:00:00

  • Management of AML: who do we really cure?

    abstract::Most clinicians caring for patients with AML do not use the word "cure" casually, since for many patients diagnosed with AML, a state of cure or even of long term survival remains elusive. Analysis of prognostic factors may aid in defining the chance for cure in various AML subtypes, and improvements are required at a...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2012.08.006

    authors: Liesveld J

    更新日期:2012-12-01 00:00:00